Supernus Pharmaceuticals, Inc. (SUPN) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$52.28
Price Target
$60.00
Target Range
$55.00 — $65.00
Analyst Rating
Buy
Forward P/E24.1x
Trailing P/E-76.9x
Forward PEG—
Implied Growth+530.7%
Median Target$60.00
Analyst Spread16.7%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$55
+5.2%
Consensus
$60
+14.8%
Bull Case
$65
+24.3%
SUPN Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Supernus Pharmaceuticals, Inc. (SUPN) has a Wall Street consensus price target of $60.00, based on estimates from 14 covering analysts. With the stock currently trading at $52.28, this represents a potential upside of +14.8%. The company has a market capitalization of $3.01B.
Analyst price targets range from a low of $55.00 to a high of $65.00, representing a 17% spread in expectations. The median target of $60.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, SUPN trades at a trailing P/E of -76.9x and forward P/E of 24.1x. Analysts expect EPS to grow +530.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+40.4%
Avg Forward P/E32.9x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PCRXPacira BioSciences, Inc. | $930M | $23.64 | $29.50 | +24.8% | Hold | 8.6x | 36 |
 ACADACADIA Pharmaceuticals Inc. | $3.9B | $22.57 | $34.78 | +54.1% | Buy | 50.9x | 37 |
 INVAInnoviva, Inc. | $1.9B | $22.80 | $37.67 | +65.2% | Buy | 11.9x | 10 |
 PRGOPerrigo Company plc | $1.6B | $11.72 | $20.00 | +70.6% | Hold | 5.6x | 36 |
 LNTHLantheus Holdings, Inc. | $5.9B | $91.00 | $101.00 | +11.0% | Buy | 17.5x | 17 |
 HRMYHarmony Biosciences Holdings, Inc. | $1.8B | $31.42 | $46.80 | +48.9% | Buy | 9.0x | 13 |
 AXSMAxsome Therapeutics, Inc. | $11.3B | $220.10 | $225.86 | +2.6% | Buy | — | 25 |
 NKTRNektar Therapeutics | $1.7B | $83.37 | $132.83 | +59.3% | Buy | — | 33 |
 LGNDLigand Pharmaceuticals Incorporated | $4.1B | $210.33 | $267.75 | +27.3% | Buy | 23.6x | 17 |
 CORTCorcept Therapeutics Incorporated | $5.5B | $51.05 | $71.67 | +40.4% | Buy | 136.0x | 25 |
Upside Potential Comparison
PRGOINVANKTRACADHRMYCORTLGNDPCRXSee SUPN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SUPN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SUPN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSUPN — Frequently Asked Questions
Quick answers to the most common questions about buying SUPN stock.
What is the SUPN stock price target for 2026?
Supernus Pharmaceuticals, Inc. (SUPN) has a consensus 12-month price target of $60, implying 14.8% upside from $52.28. The 14 analysts covering SUPN see moderate appreciation potential.
Is SUPN a buy, sell, or hold?
SUPN has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $60 implies 14.8% upside from current levels.
Is SUPN stock overvalued or undervalued?
SUPN trades at a forward P/E of 24.12x, representing a moderate valuation. With analysts targeting $60 (14.8% implied move), the stock appears reasonably valued with upside.
How high can SUPN stock go?
The most bullish Wall Street analyst has a price target of $65 for SUPN, while the most conservative target is $55. The consensus of $60 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover SUPN stock?
SUPN is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the SUPN stock forecast?
The 12-month SUPN stock forecast based on 14 Wall Street analysts shows a consensus price target of $60, with estimates ranging from $55 (bear case) to $65 (bull case). The median consensus rating is "Buy".
What is SUPN's forward P/E ratio?
SUPN trades at a forward P/E ratio of 24.1x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy SUPN stock?
Wall Street analysts are optimistic on SUPN, with a "Buy" consensus rating and $60 price target (14.8% upside). 9 of 14 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do SUPN price targets vary so much?
SUPN analyst price targets range from $55 to $65, a 17% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $60 consensus represents the middle ground.